ARGENX (ARGX) Company Report

Analyst Coverage

Research analysts who have asked questions during ARGENX earnings calls.

Derek Archila

Wells Fargo

6 questions for ARGX

Also covers: APLS, ARVN, ASND +9 more

Rajan Sharma

Goldman Sachs Group, Inc.

6 questions for ARGX

Also covers: AUTL, AZN, CVAC +6 more

Samantha Semenkow

Citigroup Inc.

6 questions for ARGX

Also covers: ALLO, BEAM, CPRX +7 more

Tazeen Ahmad

Bank of America

6 questions for ARGX

Also covers: ACAD, ALNY, APLS +20 more

Victor Floch

BNP Paribas

6 questions for ARGX

Yaron Werber

TD Cowen

6 questions for ARGX

Also covers: ALEC, AMGN, ASND +14 more

Douglas Tsao

H.C. Wainwright & Co.

5 questions for ARGX

Also covers: ALKS, APLS, ARQT +19 more

Yatin Suneja

Guggenheim Partners

5 questions for ARGX

Also covers: ACAD, AXSM, CLDX +10 more

Amy Li

Jefferies Financial Group Inc.

4 questions for ARGX

Also covers: IRWD, JAZZ, MDGL

Gavin Clark-Gartner

Evercore ISI

4 questions for ARGX

Also covers: ACRS, ASND, CMPS +11 more

Myles Minter

William Blair & Company

4 questions for ARGX

Also covers: ALEC, ARCT, AXSM +11 more

Thomas Smith

Leerink Partners

4 questions for ARGX

Also covers: ACRS, CLDX, CNTB +5 more

Xian Deng

Berenberg

4 questions for ARGX

Also covers: GLPG, GMAB

Alexander Thompson

Stifel

3 questions for ARGX

Also covers: ACRS, ASND, CRNX +4 more

Alex Thompson

Stifel Financial Corp.

3 questions for ARGX

Also covers: ASND, CRNX, KYMR +1 more

Andy Chen

Wolfe Research, LLC

3 questions for ARGX

Also covers: CRNX, IMVT, INCY +7 more

Charles Pitman-King

Barclays

3 questions for ARGX

Also covers: GRFS

Danielle Brill

Truist Securities

3 questions for ARGX

Also covers: ACAD, BBIO, HRMY +5 more

James Gordon

JPMorgan Chase & Co.

3 questions for ARGX

Also covers: AZN, GRFS, GSK

Joel Beatty

Baird

3 questions for ARGX

Also covers: ACAD, ALKS, AMLX +11 more

Suzanne van Voorthuizen

Kempen & Co

3 questions for ARGX

Also covers: BNTX, GMAB, HOOK +3 more

Vikram Purohit

Morgan Stanley

3 questions for ARGX

Also covers: ABSI, ARQT, ASND +11 more

Akash Tewari

Jefferies

2 questions for ARGX

Also covers: ALKS, APLS, ARVN +15 more

Cassie Yuan

RBC Capital Markets

2 questions for ARGX

Jacob Mekhael

KBC Securities

2 questions for ARGX

Also covers: AUTL, GLPG

Leland Gershell

Oppenheimer & Co. Inc.

2 questions for ARGX

Also covers: ASND, CAPR, CASI +13 more

Manos Mastorakis

Deutsche Bank

2 questions for ARGX

Also covers: BNTX, GLPG

Matthew Phipps

William Blair

2 questions for ARGX

Also covers: ABBV, AGEN, AMGN +8 more

Morgan

Morgan Stanley

2 questions for ARGX

Nick

Virtue Capital

2 questions for ARGX

Also covers: ARE, YI

Richard Vosser

JPMorgan Chase & Co.

2 questions for ARGX

Also covers: AZN, MOLN, NVO +2 more

Brian Conley

Leerink Partners

1 question for ARGX

Charles Pitman

Barclays PLC

1 question for ARGX

Also covers: GRFS, SOAGY

David Nierengarten

Wedbush Securities

1 question for ARGX

Also covers: ITOS, KNSA, NUVB +4 more

Maddalena Delma Caiati

Guggenheim

1 question for ARGX

Mehdi Goudarzi

Truist Securities

1 question for ARGX

Also covers: EDIT, NTLA, RARE +1 more

Nat Charoensook

Leerink Partners

1 question for ARGX

Also covers: IMUX, VKTX

Sean Laaman

Morgan Stanley & Co.

1 question for ARGX

Also covers: ACAD, AXSM, BGNE +8 more

Latest news

Recent press releases and 8-K filings for ARGX.

ARGENX Discontinues UplighTED Studies for Efgartigimod SC in Thyroid Eye Disease

ARGX

New Projects/Investments

ARGENX SE announced the discontinuation of its Phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) in adults with moderate to severe thyroid eye disease (TED).
The decision to stop the trials was based on a recommendation for futility from an Independent Data Monitoring Committee (IDMC) following a pre-specified interim analysis.
Efgartigimod demonstrated a favorable safety and tolerability profile, with no new safety signals identified during the studies.
ARGENX plans to conduct a comprehensive analysis of the data to gain insights for future research in TED, with results to be shared at a future medical meeting.

Dec 15, 2025, 11:15 AM

6-K

argenx Announces Strong Q3 2025 Financial Results with VYVGART Sales Exceeding $1 Billion

ARGX

Earnings

Product Launch

New Projects/Investments

argenx reported Q3 2025 total product net sales of $1.13 billion, marking the first time VYVGART sales surpassed $1 billion in a single quarter, representing 96% year-over-year growth.
U.S. product net sales for VYVGART reached $964 million, growing 20% quarter-over-quarter, primarily driven by the successful launch of the pre-filled syringe (PFS) and continued momentum in gMG and CIDP.
The company achieved an operating profit of $346 million and a profit after tax of $344 million for the quarter, with a cash balance of $4.3 billion at quarter-end.
argenx is expanding its pipeline, with three first-in-class molecules in Phase 3 development and plans for four new molecules in Phase 1 development by year-end 2025.
Positive ADAPT SERUM study results support a planned label expansion for VYVGART to include all three seronegative gMG subgroups, indicating a significant commercial opportunity.

Oct 30, 2025, 12:30 PM

Transcript

argenx Reports Record Q3 2025 Financial Results and Pipeline Progress

ARGX

Earnings

Revenue Acceleration/Inflection

New Projects/Investments

argenx reported record total product net sales of $1.13 billion in Q3 2025, marking the first time VYVGART sales surpassed $1 billion in a single quarter, representing 19% quarter-over-quarter growth and 96% year-over-year growth.
The pre-filled syringe (PFS) formulation of VYVGART is a key growth driver, contributing to a 20% quarter-over-quarter increase in U.S. sales and attracting over 260 new prescribers since its launch.
The company has three first-in-class molecules in Phase III development and expects five registration readouts in 2026, including for Ocular gMG, Myositis, TED, MMN, and ITP.
Positive results from the ADAPT SERON study support a planned label expansion for VYVGART to include all three seronegative gMG subgroups.
argenx ended the quarter with a strong cash balance of $4.3 billion and expects full-year 2025 operating expenses to be between $2.6 billion and $2.7 billion.

Oct 30, 2025, 12:30 PM

Transcript

argenx Reports Strong Q3 2025 Financial Results and Pipeline Advancements

ARGX

Earnings

Product Launch

Guidance Update

argenx reported Q3 2025 total product net sales of $1.13 billion, a 96% year-over-year increase, marking the first time VYVGART sales exceeded $1 billion in a single quarter.
The pre-filled syringe (PFS) formulation of VYVGART is a key growth driver, with over 50% of new patients starting on PFS and expanding the prescriber base.
The company plans to file for a label expansion for seronegative generalized Myasthenia Gravis (gMG) following positive ADAPT SERUM study results and anticipates five registration readouts in 2026 across its pipeline.
Strategic pipeline adjustments include advancing efgartigimod into Phase 3 for Graves disease while discontinuing development for empasiprubart in dermatomyositis and efgartigimod in lupus nephritis.
argenx concluded Q3 2025 with a cash balance of $4.3 billion and projects full-year combined R&D and SG&A expenses between $2.6 billion and $2.7 billion.

Oct 30, 2025, 12:30 PM

Transcript

argenx SE Reports Strong Q3 2025 Financial Results and Provides Business Update

ARGX

Earnings

Product Launch

New Projects/Investments

argenx SE reported strong financial results for Q3 2025, with $1.13 billion in global product net sales and a basic profit per share of $5.61.
The company is advancing its key product, VYVGART, with the SC prefilled syringe approved in Japan in September 2025 and a Supplemental Biologics License Application (sBLA) for seronegative gMG on track for U.S. FDA filing by year-end 2025.
argenx anticipates five registrational study readouts in 2026, including topline results for ocular MG in the first half of 2026 and primary ITP in the second half of 2026.
As of September 30, 2025, the company maintained a strong financial position with $4.3 billion in cash, cash equivalents, and current financial assets.

Oct 30, 2025, 12:04 PM

6-K

ARGENX SE Presents Positive VYVGART Data for Myasthenia Gravis

ARGX

New Projects/Investments

Revenue Acceleration/Inflection

argenx SE presented new data at the 2025 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting (AANEM) and Myasthenia Gravis Foundation of America (MGFA) Scientific Session, highlighting the efficacy and safety of VYVGART across generalized myasthenia gravis (gMG) patient populations.
The Phase 3 ADAPT SERON study met its primary endpoint, demonstrating a statistically significant improvement in MG-ADL total score for AChR-Ab seronegative gMG patients treated with VYVGART (p-value=0.0068). argenx plans to seek expansion of the VYVGART label to include this patient group.
Final ADAPT SC+ results showed that approximately 59.2% of AChR-Ab+ participants achieved minimal symptom expression (MSE) at least once, with 88.1% sustaining MSE for at least 4 weeks.
Real-world data from an IQVIA study indicated that 72.5% of patients treated with VYVGART meaningfully reduced glucocorticoid use, with the average daily dose decreasing by more than 50% (from 16.6 to 7.5 mg/day) at 18 months.

Oct 29, 2025, 3:11 PM

6-K

ARGENX Advances argenx 119 into Registrational Study for CMS and Provides Pipeline Updates

ARGX

New Projects/Investments

Guidance Update

ARGENX's Musk agonist, argenx 119, is advancing into a registrational study for Congenital Myasthenic Syndromes (CMS) following positive Phase 1B results demonstrating a favorable safety profile and proof of biology.
The Phase 1B study in DOK7 CMS patients showed improvements in mobility, with ambulatory patients achieving a median increase of 75 meters in the six-minute walk test.
Key upcoming milestones for argenx 119 include top-line results from an ALS study in the first half of 2026 and the initiation of an SMA study (named SPARKLE).
Argenx 119 is a core asset in the company's Vision 2030, contributing to the goal of reaching 50,000 patients across all medicines and 10 labeled indications.

Sep 16, 2025, 6:00 PM

Transcript

argenx Reports Positive Topline Results for VYVGART ADAPT SERON Study

ARGX

Product Launch

New Projects/Investments

argenx SE announced positive topline results from the pivotal ADAPT SERON study of VYVGART in patients with AChR-Ab seronegative generalized myasthenia gravis (gMG) on August 25, 2025.
The study met its primary endpoint (p-value=0.0068), demonstrating a statistically significant and clinically meaningful improvement in MG-ADL total score compared to placebo.
This marks the first global Phase 3 study to show clinically meaningful improvements in disease activity across all three seronegative gMG subtypes: MuSK+, LRP4+, and triple seronegative.
Based on these results, argenx plans to submit a Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) by the end of 2025 to expand the VYVGART label.